Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion

Journal of Virology

Volumn 86, Issue 3, 2012, Pages 1405-1410

  Murakami, Shin ^a,e   Horimoto, Taisuke ^a,b   Ito, Mutsumi ^a   Takano, Ryo ^a,c   Katsura, Hiroaki ^a   Shimojima, Masayuki ^a   Kawaoka, Yoshihiro ^a,c,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE;

ADAPTATION; ANIMAL CELL; ARTICLE; CELL GROWTH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANDEMIC INFLUENZA; PH; PLASMID; PRIORITY JOURNAL; PROCESS OPTIMIZATION; VACCINE PRODUCTION; VERO CELL; VIROGENESIS; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CERCOPITHECUS AETHIOPS; DOGS; HYDROGEN-ION CONCENTRATION; INFLUENZA A VIRUS; INFLUENZA VACCINES; MEMBRANE FUSION; VERO CELLS;

CERCOPITHECUS AETHIOPS;

EID: 84857067845     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06009-11     Document Type: Article

References (44)

1. Barrett PN, et al. 2011. Efficacy, safety, and immunogenicity of a Verocell-culture-derived trivalent influenza vaccine: a multicentre, doubleblind, randomised, placebo-controlled trial. Lancet 377:751-759.
2. Barrett PN, Mundt W, Kistner O, Howard MK. 2009. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev. Vaccines 8:607-618.
3. Brownlee GG, Fodor E. 2001. The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:1871-1876.
4. Clark TW, et al. 2009. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 361:2424-2435.
5. Corti D, et al. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120:1663-1673.
6. De BK, Nayak DP. 1980. Defective interfering influenza viruses and host cells: establishment and maintenance of persistent influenza virus infection in MDBK and HeLa cells. J. Virol. 36:847-859.
7. Ehrlich HJ, et al. 2009. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J. Infect. Dis. 200: 1113-1118.
8. Ehrlich HJ, et al. 2008. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358:2573-2584.
9. Ekiert DC, et al. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-251.
10. Genzel Y, Fischer M, Reichl U. 2006. Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture. Vaccine 24:3261-3272.
11. Green RF, Meiss HK, Rodriguez-Boulan E. 1981. Glycosylation does not determine segregation of viral envelope proteins in the plasma membrane of epithelial cells. J. Cell Biol. 89:230-239.
12. Gupta RK, and Nguyen-Van-Tam JS. 2006. Oseltamivir resistance in influenza A (H5N1) infection. N. Engl. J. Med. 354:1423-1424.
13. Halperin SA, et al. 2002. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20:1240-1247.
14. Harrison SC. 2008. Viral membrane fusion. Nat. Struct. Mol. Biol. 15: 690-698.
15. Horimoto T, et al. 2007. Enhanced growth of seed viruses for H5N1 influenza vaccines. Virology 366:23-27.
16. James JM, et al. 1998. Safe administration of influenza vaccine to patients with egg allergy. J. Pediatr. 133:624-628.
17. Kashyap AK, et al. 2008. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc. Natl. Acad. Sci. U. S. A. 105:5986-5991.
18. Katz JM, Webster RG. 1992. Amino acid sequence identity between the HA1 of influenza A (H3N2) viruses grown in mammalian and primary chick kidney cells. J. Gen. Virol. 73:1159-1165.
19. Keitel WA, et al. 2009. Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine 27: 6642-6648.
20. Kobasa D, et al. 2004. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 431:703-707.
21. Lakadamyali M, Rust MJ, Babcock HP, Zhuang X. 2003. Visualizing infection of individual influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 100:9280-9285.
22. Lakadamyali M, Rust MJ, Zhuang X. 2004. Endocytosis of influenza viruses. Microbes Infect. 6:929-936.
23. Le QM, et al. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108.
24. Lin YP, et al. 1997. Adaptation of egg-grown and transfectant influenza viruses for growth in mammalian cells: selection of hemagglutinin mutants with elevated pH of membrane fusion. Virology 233:402-410.
25. Marchetti A, Lelong E, Cosson P. 2009. A measure of endosomal pH by flow cytometry in Dictyostelium. BMC Res. Notes 2:7.
26. Montagnon BJ. 1989. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev. Biol. Stand. 70:27-47.
27. Murakami S, et al. 2008. Establishment of canine RNA polymerase I-driven reverse genetics for influenza A virus: its application for H5N1 vaccine production. J. Virol. 82:1605-1609.
28. Nabel GJ, Fauci AS. 2010. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat. Med. 16: 1389-1391.
29. Neumann G, et al. 1999. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. U. S. A. 96:9345-9350.
30. Octaviani CP, Ozawa M, Yamada S, Goto H, Kawaoka Y. 2010. High level of genetic compatibility between swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses. J. Virol. 84:10918-10922.
31. Ozawa M, Goto H, Horimoto T, Kawaoka Y. 2007. An adenovirus vector-mediated reverse genetics system for influenza A virus generation. J. Virol. 81:9556-9559.
32. Reed ML, et al. 2010. The pH of activation of the hemagglutinin protein regulates H5N1 influenza virus pathogenicity and transmissibility in ducks. J. Virol. 84:1527-1535.
33. Reed ML, et al. 2009. Amino acid residues in the fusion peptide pocket regulate the pH of activation of the H5N1 influenza virus hemagglutinin protein. J. Virol. 83:3568-3580.
34. Roche S, Bressanelli S, Rey FA, Gaudin Y. 2006. Crystal structure of the low-pH form of the vesicular stomatitis virus glycoprotein G. Science 313:187-191.
35. Rybak SL, Murphy RF. 1998. Primary cell cultures from murine kidney and heart differ in endosomal pH. J. Cell Physiol. 176:216-222.
36. Sieczkarski SB, Whittaker GR. 2003. Differential requirements of Rab5 and Rab7 for endocytosis of influenza and other enveloped viruses. Traffic 4:333-343.
37. Smith KA, Colvin CJ, Weber PS, Spatz SJ, Coussens PM. 2008. High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases. Vaccine 26:3778-3782.
38. Sugawara K, et al. 2002. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 30:303-314.
39. Sui J, et al. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16:265-273.
40. Wang TT, et al. 2010. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. U. S. A. 107:18979-18984.
41. WHO. 1995. Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull. World Health Organ. 73:431-435.
42. Wood JM, Robertson JS. 2004. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol. 2:842-847.
43. Xu R, Wilson IA. 2011. Structural characterization of an early fusion intermediate of influenza virus hemagglutinin. J. Virol. 85:5172-5182.
44. Yang W, Qu S, Liu Q, Zheng C. 2009. Avian influenza virus A/chicken/Hubei/489/2004 (H5N1) induces caspase-dependent apoptosis in a cellspecific manner. Mol. Cell Biochem. 332:233-241.